Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
单克隆抗体(mAbs)在过去的二十年中发展成为各种适应症的药物治疗干预的支柱,目前已有超过 40 种 mAbs 获得美国食品和药物管理局的批准,还有几十种处于临床开发阶段。本教程将回顾与 mAbs 相关的主要药物处置过程,并强调调节其药代动力学(PK)行为的产品特异性和患者特异性因素,这些因素需要在成功的临床治疗中加以考虑。